Related Experiment Video

Updated: Mar 15, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.6K

Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway

Yufu Zhu1,2, Zhichao Qiu1,3, Xiang Zhang1,3

  • 1Insititute of Nervous System Diseases, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China.

Journal of Neuro-Oncology
|September 19, 2016
PubMed

Insights

Jun activation domain-binding protein 1 (Jab1) promotes glioma cell proliferation by regulating β-catenin signaling. Inhibiting Jab1 may offer a therapeutic strategy for glioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuroscience

Background:

  • Jun activation domain-binding protein 1 (Jab1), also known as COP9 signalosome subunit 5 (CSN5), is overexpressed in various cancers.
  • The specific role and mechanisms of Jab1 in human gliomas remain largely uncharacterized.

Purpose of the Study:

  • To investigate the biological functions and molecular mechanisms of Jab1 in human glioma.
  • To determine the impact of Jab1 expression levels on glioma cell proliferation.

Main Methods:

  • Analysis of Jab1 protein expression in human glioma tissues versus non-tumor brain tissues.
  • Jab1 loss- and gain-of-function studies in glioma cells.
  • Investigation of molecular targets, including p53, Siah1, and β-catenin pathways.

Main Results:

  • Jab1 protein expression is significantly increased in human glioma tissues.
  • Downregulation of Jab1 inhibits glioma cell proliferation, while overexpression promotes it.
  • Jab1 silencing increases p53 levels, upregulating Siah1 and promoting β-catenin degradation. Conversely, Jab1 overexpression inhibits these effects.

Conclusions:

  • Jab1 promotes glioma cell proliferation, potentially by amplifying β-catenin signaling.
  • Increased Jab1 expression in glioma patients may contribute to tumor development.
  • Targeting Jab1 could be a potential therapeutic strategy for glioma.
Keywords:
GliomaJab1P53Siah1β-Catenin

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.3K
Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis07:26

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis

Published on: January 31, 2025

1.1K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K